

Pilar Rivera-Ortega

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6205080/publications.pdf>

Version: 2024-02-01

36
papers

3,821
citations

758635

12
h-index

839053

18
g-index

39
all docs

39
docs citations

39
times ranked

7962
citing authors

#	ARTICLE	IF	CITATIONS
1	Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. <i>Lancet, The</i> , 2021, 397, 1637-1645.	6.3	1,374
2	Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. <i>New England Journal of Medicine</i> , 2020, 383, 2030-2040.	13.9	1,013
3	Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study. <i>Lancet Respiratory Medicine</i> , 2021, 9, 1275-1287.	5.2	394
4	Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. <i>Lancet, The</i> , 2021, 397, 2049-2059.	6.3	391
5	Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. <i>Lancet, The</i> , 2021, 397, 605-612.	6.3	234
6	Outcome of Hospitalization for COVID-19 in Patients with Interstitial Lung Disease. An International Multicenter Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 1656-1665.	2.5	171
7	Nintedanib in the management of idiopathic pulmonary fibrosis: clinical trial evidence and real-world experience. <i>Therapeutic Advances in Respiratory Disease</i> , 2018, 12, 175346661880061.	1.0	59
8	The characterisation of interstitial lung disease multidisciplinary team meetings: A global study. <i>ERJ Open Research</i> , 2019, 5, 00209-2018.	1.1	49
9	Interstitial Lung Diseases in Developing Countries. <i>Annals of Global Health</i> , 2019, 85, .	0.8	37
10	Understanding the burden of interstitial lung disease post-COVID-19: the UK Interstitial Lung Disease-Long COVID Study (UKILD-Long COVID). <i>BMJ Open Respiratory Research</i> , 2021, 8, e001049.	1.2	28
11	Pulmonary Sequelae at 4 Months After COVID-19 Infection: A Single-Centre Experience of a COVID Follow-Up Service. <i>Advances in Therapy</i> , 2021, 38, 4505-4519.	1.3	23
12	Mapping IPF helps identify geographic regions at higher risk for disease development and potential triggers. <i>Respirology</i> , 2021, 26, 352-359.	1.3	18
13	Different Faces of Idiopathic Pulmonary Fibrosis With Preserved Forced Vital Capacity. <i>Archivos De Bronconeumologia</i> , 2022, 58, 135-141.	0.4	6
14	Trabecular bone score in active or former smokers with and without COPD. <i>PLoS ONE</i> , 2019, 14, e0209777.	1.1	6
15	Exploring the Association Between Emphysema Phenotypes and Low Bone Mineral Density in Smokers with and without COPD. <i>International Journal of COPD</i> , 2020, Volume 15, 1823-1829.	0.9	5
16	Smoking cessation: strategies and effects in primary and secondary cardiovascular prevention. <i>Panminerva Medica</i> , 2021, 63, 110-121.	0.2	4
17	An update on interstitial lung disease. <i>British Journal of Hospital Medicine (London, England)</i> : 2005), 2021, 82, 1-14.	0.2	2
18	Introducing a new formulation of pirfenidone to reduce tablet burden for the IPF patient: Is it tolerable? Is it easy to take? What do our patients think?., 2018, .		1

#	ARTICLE	IF	CITATIONS
19	Mapping IPF helps identify geographic regions at higher risk for disease development. , 2020, , .		1
20	Rapidly non-ipf progressive fibrosing interstitial lung disease: a phenotype with an ipf-like behavior. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2020, 37, 231-233.	0.2	1
21	Relevance of the expert ILD clinical-radiological evaluation of referred cases to the MDT. , 2016, , .		1
22	Reply to Althwaybi et al.: Hospitalization Outcomes for COVID-19 in Patients with Interstitial Lung Disease: A Potential Role for Aerodigestive Pathophysiology?. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 522-524.	2.5	0
23	The potential value of FRAX index and bone turnover markers to identify osteoporosis in COPD patients. , 2015, , .		0
24	Factors determining the presence of osteoporosis in active and former smokers. , 2016, , .		0
25	Bone attenuation on chest computed tomography correlates with bone mineral density on densitometry in patients with emphysema and COPD. , 2016, , .		0
26	Benefits from a program for "early interstitial lung diseases" in primary care centers. , 2017, , .		0
27	The impact of a network based approach on lung function and symptom duration at diagnosis in idiopathic pulmonary fibrosis. , 2018, , .		0
28	What can we learn from Idiopathic Pulmonary Fibrosis Registries?. , 2018, , .		0
29	Antifibrotic choice in idiopathic pulmonary fibrosis. , 2018, , .		0
30	Score for the identification of osteoporosis in smokers (SIOS): its development using clinical, radiological and biochemical information. , 2018, , .		0
31	Predictive variables to obtain a bronchoalveolar lavage of adequate quality in patients with interstitial lung diseases. , 2019, , .		0
32	Association of demographic, laboratory and clinical parameters with HRCT-chest findings in patients with sarcoidosis. , 2019, , .		0
33	Safety and tolerability of immunosuppression in non-IPF ILD: clinical experience from a tertiary ILD centre. , 2019, , .		0
34	Improving adherence to treatment in patients with obstructive sleep apnoea. , 2019, , .		0
35	P56"..."What happens to patients with idiopathic pulmonary fibrosis who are not eligible for antifibrotic treatment due to current NICE guidelines. , 2019, , .		0
36	Preserved Forced Vital Capacity is not Always Representing Early IPF. , 2020, , .		0